Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting

Summary

There are two principal cyclooxygenase isoforms referred to as COX-1 and COX-2. Recently, COX-3 has been identified. We have demonstrated the expression of COX-2 in platelets from patients after coronary artery bypass grafting (CABG). Careful biochemical analysis revealed that, when compared to recombinant COX-2, platelet COX-2 had a slightly higher electrophoretic mobility. Two COX-2 sequences (∼1.8 kb, ∼1.7 kb) were cloned from platelet mRNA. The ∼1.7 kb sequence, designated COX-2a, differed from the human COX-2 sequence only in a deletion from position +458 to +567. Similar to the human COX-3, there is a frame shift in the COX-2a sequence resulting in a TAA stop codon at position +490. Thus, the expression of a COX-2a protein corresponding to the 67 kDa COX-2 protein is not clear. However, the marked shifting from COX-2 to COX-2a in platelets from some patients after CABG is a striking finding.

Keywords

Cyclooxygenase-2 - splice variant - platelets - coronary artery bypass grafting

• References

• 1 Smith WL, Garavito RM, DeWitt RM. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-60.
• 2 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.
• 3 Chandrasekharan NV, Dai H, Roos LT. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
• 4 Matijevic-Aleksic N, Sanduja SK, Wang L-H. et al. Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta 1995; 1269: 167-75.
• 5 Weber A-A, Zimmermann KC, Meyer-Kirchrath J. et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
• 6 Weber A-A, Przytulski B, Schumacher M. et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002; 117: 424-6.
• 7 Zimmermann N, Wenk A, Kim U-H. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary bypass surgery. Circulation 2003; 108: 542-7.
• 8 Patrignani P, Sciulli MG, Manarini S. et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 63: 661-7.
• 9 Reiter R, Resch U, Sinzinger H. Do human platelets express COX-2?. Prostaglandins Leukotr Essent Fatty Acids 2001; 64: 299-305.
• 10 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
• 11 Tanaka N, Sato T, Fujita H. et al. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler Thromb Vasc Biol 2004; 24: 607-12.
• 12 Weber A-A, Liesener S, Schanz A. et al. Habitual smoking causes an abnormality in platelet thromboxane A₂ metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000; 11: 177-82.
• 13 Weber A-A, Schrör K. Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001; 08: 1619-21.
• 14 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
• 15 Schwab JM, Beiter T, Linder JU. et al. COX-3 – a virtual pain target in humans?. FASEB J 2003; 17: 2174-5.
• 16 Weber A-A, Przytulski B, Schanz A. et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40.